29 January 2020 - The global Gastroesophageal
Reflux Disease (GERD) Therapeutics Market size was valued at USD 5.66 billion in 2016 and by is estimated to be
USD 4.34 billion by 2025, it is anticipated to observe a decrease in its
revenue at a negative CAGR of -2.9%. Expiration of patented blockbuster drugs,
which are indicated for the management of disorders of acid reflux is major
restraining factors for this market.
With
strong clinical pipelines and patent litigations, the market continues to
experience significant changes. Proton pump inhibitors (PPI) and antagonists of
histamine H2 receptor have the importance in current scenario of the market.
Upon
loss of patent protection of formerly leading branded drugs, generic molecules
with low-price can ingest the sales of the branded ones up to 90%. Rising
number of companies being exposed to price scrutiny associated with shift in
the focus of government on the promotion of consumer convenience will stimulate
further reduction of drug prices. Although market turnover is affected by the
expiration of major patents and the demand of drugs used to reduce acid, due to
the increasing prevalence of heartburn, is anticipated to increase in the
upcoming years.
The
devices of GERD serves as a substitute for management of heartburn, because of
low rate of success and failure in clinical trials. Hence, very limited
acceptance of devices of GERD management contribute for the rising demand of
drugs having acid neutralizing property, as the major therapy approach.
Nevertheless,
the advent of devices which are minimally invasive to address anatomical
defects are gaining popularity coupled with supportive evidence from clinical
data for performing various procedures including trans oral fundoplication,
which helps in preventing reflux of non-acid and acid contents. The adoption of
these devices have been further reinforced in the U.S. in 2016 with the advent
of a CPT code (43210) which helps in facilitating reimbursement process.
Drug Type Insights
In
2016, market was dominated by the antacids segment and is anticipated to keep
its top position over the forecast period. Most preferred first-line therapy
for infrequent and mild symptoms is antacids, as the therapy neutralize the
secretion of gastric acid immediately. Convenient OTC (over-the-counter)
accessibility various forms such as syrups, powders and tablets is accountable
for the extreme adoption. Moreover, the AHFS (American Hospital Formulary
services), amongst other countries, enlisted over 120 preparations too
advocate.
In
2016, the second largest segment was found to be PPIs as it is the most common
medication prescription type for the diseases such as heartburn. Generics
inflow leading to the loss of exclusiveness of popular drugs, including
Prilosec and Nexium, is estimated to negatively affect the sales of branded
versions. A further decrease is appearing more with the expected expiration of
other patented drugs, such as Dexilant.
Regional Insights
In
2016, the largest region was found to be North America in terms of share for
GERD market. Every year, GERD symptoms are experienced by more than 80 million
people in the U.S., of which, approximately 25 million patients suffer from
acid reflux and heartburn daily and approximately 60 million patients monthly.
Moreover,
outpatient clinic visits for GERD disorder in the U.S. has been increased in
the past few years because of the more prone geriatric population to develop
acid reflux and heartburn. On the contrary, the Asia Pacific is estimated to
witness the fastest growth rate. The increasing geriatric population and
dietary and lifestyle risk factors such as diet with high fat and obesity, is
anticipated to drive the growth. In developing countries, the inclination
towards self-medication is quickly increasing because of the affordability and
availability of OTC antacids as in China and India.
Competitive Insights
Competitive
market, which is generics-driven is creating a pressure on the prices of drug
with decreased retail sales, which will stimulate stationary growth in future.
Companies producing them range from high to medium on the basis of competitive
rivalry. Eisai Co., Ltd.; AstraZeneca PLC; GlaxoSmithKline PLC; Johnson &
Johnson and Takeda Pharmaceutical Co., Ltd.; are some of the top key players.
In addition, Daewoong Pharmaceutical Co., Ltd.; SRS Pharmaceuticals Pvt. Ltd.;
SFJ Pharmaceuticals Group and Ironwood Pharmaceuticals, Inc. are some emerging
companies.
Among
others, RaQualia Pharma, Inc. and Ironwood Pharmaceuticals, Inc. are focusing
more on development of new generic molecules, which involves novel and existing
drug mechanisms as a part of the strategy to enter into the competition. Many
generic players are also trying to focus on these spaces in an attempt to
capture a larger share by the new version to replace the patent expired drugs.
Market Segment:
GERD Therapeutics Drug Type Outlook
(Revenue, USD Million, 2014 - 2025)
• Antacids
• H2 Receptor Blockers
• Proton Pump Inhibitors (PPIs)
• Pro-kinetic agents
GERD Therapeutics Regional Outlook
(Revenue, USD Million, 2014 - 2025)
• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• Asia Pacific
• Japan
• China
• India
• Latin America
• Brazil
• Middle East and Africa (MEA)
• South Africa
Comments
Post a Comment